JP2013537901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537901A5 JP2013537901A5 JP2013529758A JP2013529758A JP2013537901A5 JP 2013537901 A5 JP2013537901 A5 JP 2013537901A5 JP 2013529758 A JP2013529758 A JP 2013529758A JP 2013529758 A JP2013529758 A JP 2013529758A JP 2013537901 A5 JP2013537901 A5 JP 2013537901A5
- Authority
- JP
- Japan
- Prior art keywords
- aprepitant
- proline
- neuropsychiatric
- pruritus
- cancers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ATALOFNDEOCMKK-OITMNORJSA-N Aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims 7
- 229960001372 aprepitant Drugs 0.000 claims 7
- 206010022114 Injury Diseases 0.000 claims 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 208000003251 Pruritus Diseases 0.000 claims 4
- 206010038683 Respiratory disease Diseases 0.000 claims 4
- 208000006641 Skin Disease Diseases 0.000 claims 4
- 206010047700 Vomiting Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 200000000018 inflammatory disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- VPZQPVZMZHUTTF-WCCKRBBISA-N (2S)-pyrrolidine-2-carboxylic acid;hydrate Chemical compound O.OC(=O)[C@@H]1CCCN1 VPZQPVZMZHUTTF-WCCKRBBISA-N 0.000 claims 3
- 230000000607 poisoning Effects 0.000 claims 3
- 231100000572 poisoning Toxicity 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 231100000614 Poison Toxicity 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Claims (9)
- １：１：１アプレピタントＬ−プロリンＨ２Ｏ共結晶。
- 以下の少なくとも１つを特徴とする１：１：１アプレピタントＬ−プロリンＨ２Ｏ共結晶：
６．４、９．４、１１．９、１２．９、１４．６、および１８．８（°２θ±０．２°２θ）から選択される少なくとも３つのピークを有する粉末Ｘ線回折パターン；
図１
に類似した粉末Ｘ線回折パターン；
２９４Ｋの温度でのＰ２１２１２１空間群；または
２９４Ｋの温度でのａ＝９．１９６３（４）Å、ｂ＝１２．８３３２（９）Å、ｃ＝２７．４２８９（１９）Å、α＝９０°、β＝９０°、およびγ＝９０°の単位格子寸法。 - 請求項１または２の１：１：１アプレピタントＬ−プロリンＨ２Ｏ共結晶および薬学的に許容される担体を含む医薬組成物。
- 治療有効量の請求項１または２の１：１：１アプレピタントＬ−プロリンＨ２Ｏ共結晶を含む、嘔吐に関連する傷害、神経精神病、炎症性疾患、疼痛、癌、皮膚疾患、掻痒、呼吸器疾患、または中毒を処置または予防するための医薬。
- 嘔吐に関連する傷害、神経精神病、炎症性疾患、疼痛、癌、皮膚疾患、掻痒、呼吸器疾患、または中毒を処置または予防するための請求項３の医薬組成物。
- １：１：１アプレピタントＬ−プロリン水和物。
- 請求項６の１：１：１アプレピタントＬ−プロリン水和物および薬学的に許容される担体を含む医薬組成物。
- 治療有効量の請求項６の１：１：１アプレピタントＬ−プロリン水和物を含む、嘔吐に関連する傷害、神経精神病、炎症性疾患、疼痛、癌、皮膚疾患、掻痒、呼吸器疾患、または中毒を処置または予防するための医薬。
- 嘔吐に関連する傷害、神経精神病、炎症性疾患、疼痛、癌、皮膚疾患、掻痒、呼吸器疾患、または中毒を処置または予防するための請求項７の医薬組成物。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38574410P | 2010-09-23 | 2010-09-23 | |
| US61/385,744 | 2010-09-23 | ||
| US201161439654P | 2011-02-04 | 2011-02-04 | |
| US61/439,654 | 2011-02-04 | ||
| US201161498214P | 2011-06-17 | 2011-06-17 | |
| US61/498,214 | 2011-06-17 | ||
| PCT/IB2011/054210 WO2012038937A1 (en) | 2010-09-23 | 2011-09-23 | Aprepitant l-proline composition and cocrystal |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537901A JP2013537901A (ja) | 2013-10-07 |
| JP2013537901A5 true JP2013537901A5 (ja) | 2016-02-12 |
| JP5997162B2 JP5997162B2 (ja) | 2016-09-28 |
Family
ID=44907915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529758A Active JP5997162B2 (ja) | 2010-09-23 | 2011-09-23 | アプレピタントｌ−プロリン組成物および共結晶 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9029369B2 (ja) |
| EP (1) | EP2618828B1 (ja) |
| JP (1) | JP5997162B2 (ja) |
| KR (1) | KR101833578B1 (ja) |
| CN (1) | CN103221049B (ja) |
| AR (1) | AR083095A1 (ja) |
| AU (1) | AU2011306391B2 (ja) |
| BR (1) | BR112013006651A2 (ja) |
| CA (1) | CA2846460C (ja) |
| ES (1) | ES2616752T3 (ja) |
| HK (1) | HK1187554A1 (ja) |
| IL (1) | IL225443A0 (ja) |
| TW (1) | TWI540131B (ja) |
| WO (1) | WO2012038937A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5997162B2 (ja) | 2010-09-23 | 2016-09-28 | ナフォーミックス リミテッド | アプレピタントｌ−プロリン組成物および共結晶 |
| CN104159584A (zh) | 2011-11-25 | 2014-11-19 | 诺弗米克斯有限公司 | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 |
| US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
| US20160324881A1 (en) * | 2013-12-30 | 2016-11-10 | Oncoprevent Gmbh | Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer |
| EP3749675A1 (en) | 2018-02-07 | 2020-12-16 | Reata Pharmaceuticals, Inc. | Co-crystal forms of a novobiocin analog and proline |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| ZA985765B (en) | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| US20050025791A1 (en) * | 2002-06-21 | 2005-02-03 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
| ATE550022T1 (de) * | 2003-02-28 | 2012-04-15 | Mcneil Ppc Inc | Pharmazeutische mischkristalle von celecoxib- nicotinamid |
| EP2034952A4 (en) * | 2006-06-16 | 2011-08-17 | Reddys Lab Ltd Dr | APREPITANT COMPOSITIONS |
| US20110009362A1 (en) * | 2008-02-27 | 2011-01-13 | Dr. Reddy's Laboratories Ltd. | Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof |
| JP5997162B2 (ja) | 2010-09-23 | 2016-09-28 | ナフォーミックス リミテッド | アプレピタントｌ−プロリン組成物および共結晶 |
-
2011
- 2011-09-23 JP JP2013529758A patent/JP5997162B2/ja active Active
- 2011-09-23 BR BR112013006651A patent/BR112013006651A2/pt not_active Application Discontinuation
- 2011-09-23 EP EP11779217.6A patent/EP2618828B1/en active Active
- 2011-09-23 US US13/825,380 patent/US9029369B2/en active Active
- 2011-09-23 AR ARP110103486 patent/AR083095A1/es unknown
- 2011-09-23 ES ES11779217.6T patent/ES2616752T3/es active Active
- 2011-09-23 CN CN201180055997.5A patent/CN103221049B/zh active Active
- 2011-09-23 KR KR1020137010228A patent/KR101833578B1/ko active IP Right Grant
- 2011-09-23 TW TW100134362A patent/TWI540131B/zh active
- 2011-09-23 WO PCT/IB2011/054210 patent/WO2012038937A1/en active Application Filing
- 2011-09-23 AU AU2011306391A patent/AU2011306391B2/en active Active
- 2011-09-23 CA CA2846460A patent/CA2846460C/en active Active
-
2013
- 2013-03-21 IL IL225443A patent/IL225443A0/en active IP Right Grant
-
2014
- 2014-01-23 HK HK14100748.9A patent/HK1187554A1/zh unknown